Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases.

Nishimura Y, Maeda M, Kumagai-Takei N, Lee S, Matsuzaki H, Wada Y, Nishiike-Wada T, Iguchi H, Otsuki T.

Environ Health Prev Med. 2013 May;18(3):198-204. doi: 10.1007/s12199-013-0333-y. Epub 2013 Mar 6. Review.

2.

Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers.

Nishimura Y, Miura Y, Maeda M, Kumagai N, Murakami S, Hayashi H, Fukuoka K, Nakano T, Otsuki T.

Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):579-90.

PMID:
19822075
3.

Suppressive effect of asbestos on cytotoxicity of human NK cells.

Nishimura Y, Kumagai N, Maeda M, Hayashi H, Fukuoka K, Nakano T, Miura Y, Hiratsuka J, Otsuki T.

Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1 Suppl):5S-10S. Review.

PMID:
21329559
4.

Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients.

Nishimura Y, Kumagai-Takei N, Matsuzaki H, Lee S, Maeda M, Kishimoto T, Fukuoka K, Nakano T, Otsuki T.

Biomed Res Int. 2015;2015:238431. doi: 10.1155/2015/238431. Epub 2015 Jun 16. Review.

5.

[Immunological aspects of asbestos-related diseases].

Kanceljak-Macan B.

Arh Hig Rada Toksikol. 2009 Nov;60 Suppl:45-50. Croatian.

PMID:
20853778
6.

Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.

Maeda M, Nishimura Y, Hayashi H, Kumagai N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T, Otsuki T.

Am J Respir Cell Mol Biol. 2011 Oct;45(4):795-803. doi: 10.1165/rcmb.2010-0435OC. Epub 2011 Feb 25.

PMID:
21357438
7.
9.

The alveolar macrophage: immune derangement and asbestos-related malignancy.

Kagan E.

Semin Oncol. 1981 Sep;8(3):258-67. No abstract available.

PMID:
7280710
10.

Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.

Attanoos RL, Thomas DH, Gibbs AR.

Histopathology. 2003 Oct;43(4):387-92.

PMID:
14511258
11.

Molecular basis of asbestos-induced lung disease.

Liu G, Cheresh P, Kamp DW.

Annu Rev Pathol. 2013 Jan 24;8:161-87. doi: 10.1146/annurev-pathol-020712-163942. Review.

12.

High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma.

Lew F, Tsang P, Holland JF, Warner N, Selikoff IJ, Bekesi JG.

J Clin Immunol. 1986 May;6(3):225-33.

PMID:
2424930
13.

Asbestos toxicity: an immunologic perspective.

Rosenthal GJ, Simeonova P, Corsini E.

Rev Environ Health. 1999 Jan-Mar;14(1):11-20. Review.

PMID:
10372416
14.

Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma.

Kumagai-Takei N, Nishimura Y, Maeda M, Hayashi H, Matsuzaki H, Lee S, Kishimoto T, Fukuoka K, Nakano T, Otsuki T.

J Immunol Res. 2014;2014:670140. doi: 10.1155/2014/670140. Epub 2014 Jun 18.

15.

Cellular and molecular basis of the asbestos-related diseases.

Rom WN, Travis WD, Brody AR.

Am Rev Respir Dis. 1991 Feb;143(2):408-22. Review.

PMID:
1990961
16.

Alveolar macrophage cytokine and growth factor production in a rat model of crocidolite-induced pulmonary inflammation and fibrosis.

Driscoll KE, Maurer JK, Higgins J, Poynter J.

J Toxicol Environ Health. 1995 Oct;46(2):155-69.

PMID:
7563215
17.

Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.

Cvitanović S, Znaor L, Konsa T, Ivancević Z, Perić I, Erceg M, Vujović M, Vuković J, Beg-Zec Z.

Croat Med J. 2003 Oct;44(5):618-25.

18.

Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases.

Roggli VL, Pratt PC, Brody AR.

Br J Ind Med. 1986 Jan;43(1):18-28.

19.

Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.

Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BW.

Clin Immunol Immunopathol. 1989 Oct;53(1):68-77.

PMID:
2788546
20.

Diseases caused by asbestos: mechanisms of injury and disease development.

Manning CB, Vallyathan V, Mossman BT.

Int Immunopharmacol. 2002 Feb;2(2-3):191-200. Review.

PMID:
11811924
Items per page

Supplemental Content

Write to the Help Desk